News

Syngene International extends collaboration with Amgen till 2026

Under the extended contract, the dedicated R&D centre, ‘Syngene Amgen Research and Development Center’ will continue to conduct drug discovery and development projects as part of Amgen’s global R&D programme

Syngene International announced the extension of its long-standing multi-discipline research collaboration with Amgen, a leading biotechnology company. The contract is currently extended until the end of 2026 and its scope includes integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. In addition to operating the existing Syngene Amgen R&D Center (SARC), under the new contract, Syngene will also build and operate a dedicated laboratory that will enable R&D project acceleration. 

THIS CAN BE YOUR ADVERTISEMENT

Jonathan Hunt, CEO and MD, Syngene International, said, “While SARC was established in 2016, our collaboration with Amgen dates back to 2012. During this time, we have partnered on research and development to address some of the most serious diseases in the world. We have progressively expanded our areas of collaboration, co-authored research papers on novel science and supported the advancement of multiple development projects, while adhering to global standards of quality and safety. We are proud to have played a role in advancing molecules that are making a difference to patients around the world today. We are delighted with our joint commitment to not only extend the term of this partnership but also add a new state-of-the-art facility to the collaboration.”  

“Amgen is pleased with the success of the long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials,” said Margaret Chu-Moyer, VP of Research and Head of Chemistry, Characterization & Technology at Amgen. “We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.”  

SARC was established in 2016 and Syngene announced the expansion of the originally dedicated centre in 2017. It currently consists of 60,000 sq. ft. of floor space and a dedicated team of multi-disciplinary Syngene scientists who work closely with Amgen researchers around the world on the discovery and development of innovative medicines. 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close